Toxic neuropathy

Current Opinion in Neurology

Volumn 18, Issue 5, 2005, Pages 574-580

  Umapathi, Thirugnanam ^a   Chaudhry, Vinay ^a  

^a NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

Author keywords

Chemotherapy agents; Erythropoietin; FK 506; Gene therapy; Neuropathy models; Neurotrophic factors; Statin; Toxic neuropathy; VEGF; Vitamin E

Indexed keywords

ACRYLAMIDE; ALPHA TOCOPHEROL; AMIFOSTINE; ANTIRETROVIRUS AGENT; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIZOCILPINE; DOXORUBICIN; EPOTHILONE A; EPOTHILONE B; ERYTHROPOIETIN; ETHOSUXIMIDE; GINKGO BILOBA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEFLUNOMIDE; LEUKEMIA INHIBITORY FACTOR; NERVE GROWTH FACTOR; NEUROIMMUNOPHILIN; NEUROTROPHIN 3; OXALIPLATIN; PACLITAXEL; PYRIDOXINE; TACROLIMUS; THALIDOMIDE; THIOCTIC ACID; UNINDEXED DRUG; VASCULOTROPIN;

ANTIOXIDANT ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BREAST CANCER; CLINICAL TRIAL; CONCENTRATION RESPONSE; DIABETIC NEUROPATHY; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HEART PROTECTION; HUMAN; META ANALYSIS; MULTIPLE MYELOMA; NERVE REGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW;

EID: 26944446961     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wco.0000180158.34713.aa     Document Type: Review

References (64)

1. Kirchmair R, Walter DH, Ii M, et al. Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth. Circulation 2005; 111:2662-2670. This study showed that microvascular damage may be the basis for the toxic neuropathy induced by cisplatin, and gene therapy with VEGF may prevent or treat the neuropathy without compromising cisplatin's anti-tumour effects.
2. Schratzberger P, Walter DH, Rittig K, et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 2001; 107:1083-1092.
3. Chattopadhyay M, Goss J, Wolfe D, et al. Protective effect of herpes simplex virus-mediated neurotrophin gene transfer in cisplatin neuropathy. Brain 2004; 127:929-939. This reports on the protective effect of nerve growth factor/neurotrophin-3 expressing vectors against experimental cisplatin-induced neuropathy.
4. Chattopadhyay M, Wolfe D, Huang S, et al. In vivo gene therapy for pyridoxine-induced neuropathy by herpes simplex virus-mediated gene transfer of neurotrophin-3. Ann Neurol 2002; 51:19-27.
5. Chattopadhyay M, Goss J, Lacomis D, et al. Protective effect of HSV-mediated gene transfer of nerve growth factor in pyridoxine neuropathy demonstrates functional activity of trkA receptors in large sensory neurons of adult animals. Eur J Neurosci 2003; 17:732-740.
6. Goss JR, Goins WF, Lacomis D, et al. Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced diabetes in the mouse. Diabetes 2002; 51:2227-2232.
7. Chattopadhyay M, Wolfe D, Mata M, et al. Long-term neuroprotection achieved with latency-associated promoter-driven herpes simplex virus gene transfer to the peripheral nervous system. Mol Ther 2005 [Epub ahead of print]. Gene therapy with nerve growth factor or neurotrophin-3 driven by HSV latency-associated promoter-2 can protect against the neurotoxic effect of high-dose pyridoxine up to 6 months later.
8. Argyriou AA, Chroni E, Koutras A, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 2005;64:26-31. This describes a pilot randomized open label controlled trial (with blinded assessment) on the role of vitamin E supplementation to protect against chemotherapy-induced peripheral neuropathy. The authors showed that the group that received vitamin E had a lower incidence of neuropathy than controls.
9. Chaudhry V, Rowinsky EK, Sartorius SE, et al. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 1994; 35:304-311.
10. Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 2004; 21:114-121. This meta-analysis suggests that 3 weeks of treatment with α-lipoic acid (600mg/day intravenously) improves neuropathic symptoms and deficits in diabetic polyneuropathy.
11. Openshaw H, Beamon K, Synold TW, et al. Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine. Clin Cancer Res 2004; 10:461-467. This was a negative study, but one that illustrated the consistent induction of neuropathy by chemotherapy agents such as high-dose paclitaxel. These circumstances provide an opportunity to test the effectiveness of putative neuroprotective agents.
12. Ozturk G, Erdogan E, Anlar O, et al. Effect of leukemia inhibitory factor in experimental cisplatin neuropathy in mice. Cytokine 2005; 29:31-41. This study examined the possible therapeutic role of LIF in experimental cisplatin neuropathy.
13. Davis ID, Kiers L, MacGregor L, et al. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res 2005; 11:1890-1898. This randomized double-blind placebo-controlled phase II clinical trial showed the inability of LIF to prevent peripheral neuropathy caused by carboplatin and paclitaxel.
14. Mottram DS, Wedzicha BL, Dodson AT. Acrylamide is formed in the Maillard reaction. Nature 2002; 419:448-449.
15. Stadler RH, Blank I, Varga N, et al. Acrylamide from Maillard reaction products. Nature 2002; 419:449-450.
16. Rosen J, Hellenas KE. Analysis of acrylamide in cooked foods by liquid chromatography tandem mass spectrometry. Analyst 2002; 127:880-882.
17. Tareke E, Rydberg P, Karlsson P, et al. Analysis of acrylamide, a carcinogen formed in heated foodstuffs. J Agric Food Chem 2002; 50:4998-5006.
18. Gold BG, Voda J, Yu X, Gordon H. The immunosuppressant FK506 elicits a neuronal heat shock response and protects against acrylamide neuropathy. Exp Neurol 2004; 187:160-170. This study examined the effect of FK-506 in preventing acrylamide-induced neuropathy via the induction of heat shock protein 70. This paper is accompanied by a detailed discussion of the possible mechanism underlying axonal protection by FK-506.
19. Keswani SC, Chander B, Hasan C, et al. FK506 is neuroprotective in a model of antiretroviral toxic neuropathy. Ann Neurol 2003; 53:57-64.
20. Gold BG, Densmore V, Shou W, et al. Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506. J Pharmacol Exp Ther 1999; 289:1202-1210.
21. Gold BG. Neuroimmunophilin ligands and the role of steroid hormone chaperone proteins in nerve regeneration. In: Gold BG, Fischer G, Herdegen T, editors. Immunophilins in the brain, FKBP-ligands: novel strategies for the treatment of neurodegenerative disorders. Barcelona: Prous Science; 2000. pp. 3-22.
22. Gold BG. Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders. Expert Opin Investig Drugs 2000; 9:2331-2342.
23. Gold BG, Villafranca JE. Neuroimmunophilin ligands: the development of novel neuroregenerative/neuroprotective compounds. Curr Top Med Chem 2003; 3:1368-1375.
24. Keswani SC, Leitz GJ, Hoke A. Erythropoietin is neuroprotective in models of HIV sensory neuropathy. Neurosci Lett 2004; 371:102-105. Erythropoietin prevents axonal degeneration and neuronal death in an in-vitro model of gp120 and ddC induced neuropathy.
25. Keswani SC, Buldanlioglu U, Fischer A, et al. A novel endogenous erythropoietin mediated pathway prevents axonal degeneration. Ann Neurol 2004; 56:815-826. This study reported that in response to axonal injury periaxonal Schwann cells release erythropoietin that binds to receptors on neurons and prevents axonal injury. The authors also demonstrate a therapeutic effect of erythropoietin in an animal model of neuropathy.
26. Ozturk G, Anlar O, Erdogan E, et al. The effect of Ginkgo extract EGb761 in cisplatin-induced peripheral neuropathy in mice. Toxicol Appl Pharmacol 2004; 196:169-175. A ginkgo extract may prevent some functional and morphological deteriorations of cisplatin neuropathy induced neuropathy in mice.
27. Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel and vincristine-induced painful peripheral neuropathy. Pain 2004; 109:150-161. Ethosuximide produces a near complete reversal of paclitaxel and vincristine induced pain in rats. In addition, ethosuximide has an analgesic effect that is dose-related and non-cumulative, raising the possibility of using ethosuximide as a therapeutic agent for chemotherapy-induced pain.
28. Wang MS, Davis AA, Culver DG, et al. Calpain inhibition protects against Taxol-induced sensory neuropathy. Brain 2004; 127:671-679. AK-295, a compound that inhibits calpains, is protective against Taxol-induced peripheral neuropathy in mice. This study also raised the possibility of using such compounds in other chronic axonal polyneuropathies in which calpains may play a pathological role.
29. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
30. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307.
31. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-1009.
32. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. Jama 1998; 279:1615-1622.
33. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in lschaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339:1349-1357.
34. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
35. Jacobs MB. HMG-CoA reductase inhibitor therapy and peripheral neuropathy. Ann Intern Med 1994; 120:970.
36. Jeppesen U, Gaist D, Smith T, Sindrup SH. Statins and peripheral neuropathy. Eur J Clin Pharmacol 1999; 54:835-838.
37. Ahmad S. Lovastatin and peripheral neuropathy. Am Heart J 1995; 130:1321.
38. Phan T, McLeod JG, Pollard JD, et al. Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry 1995; 58:625-628.
39. Silverberg C. Atorvastatin-induced polyneuropathy. Ann Intern Med 2003; 139:792-793.
40. Gaist D, Garcia Rodriguez LA, Huerta C, et al. Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur J Clin Pharmacol 2001; 56:931-933.
41. Gaist D, Jeppesen U, Andersen M, et al. Statins and risk of polyneuropathy: a case-control study. Neurology 2002; 58:1333-1337.
42. Hughes RA, Umapathi T, Gray IA, et al. A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy. Brain 2004; 127:1723-1730.
43. Singleton JR, Smith AG, Russell J, Feldman EL. Polyneuropathy with Impaired Glucose Tolerance: Implications for Diagnosis and Therapy. Curr Treat Options Neurol 2005; 7:33-42.
44. Rajabally YA, Varakantam V, Abbott RJ. Disorder resembling Guillain-Barre syndrome on initiation of statin therapy. Muscle Nerve 2004; 30:663-666. The authors describe a case of acute neuropathy developing twice; and each time on exposure to statins.
45. Lo YL, Leoh TH, Loh LM, Tan CE. Statin therapy and small fibre neuropathy: a serial electrophysiological study. J Neurol Sci 2003; 208:105-108.
46. Briani C, Zara G, Rondinone R, et al. Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus. Neurology 2004; 62:2288-2290. A series consisting of 14 patients with cutaneous lupus erythematosus were given thalidomide. Seven developed a sensory axonal neuropathy.
47. Hamanoue M, Middleton G, Wyatt S, et al. p75-mediated NF-kappaB activation enhances the survival response of developing sensory neurons to nerve growth factor. Mol Cell Neurosci 1999; 14:28-40.
48. Chaudhry V, Comblath DR, Corse A, et al. Thalidomide-induced neuropathy. Neurology 2002; 59:1872-1875.
49. Isoardo G, Bergui M, Durelli L, et al. Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features. Acta Neurol Scand 2004; 109:188-193. This describes a case series of six patients with multiple myeloma who developed sensory neuropathy from thalidomide. One patient had magnetic resonance abnormalities in the posterior column and delayed central conduction time, suggesting neuronal involvement.
50. Giannini F, Volpi N, Rossi S, et al. Thalidomide-induced neuropathy: a ganglionopathy? Neurology 2003; 60:877-878.
51. Cavaletti G, Beronio A, Reni L, et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 2004; 62:2291-2293. This was a study of 65 patients taking thalidomide for various indications. It emphasized the sensitivity of monitoring serial sensory amplitudes in detecting neuropathy in patients taking thalidoamide. The neuropathy appears to be dose-dependent. The authors feel that earlier reports not showing dose-dependency might not have been adequately powered in view of the low doses of thalidomide used.
52. Maurer T, Poncelet A, Berger T. Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. Arch Dermatol 2004; 140:845-849. About one third of 10 HIV patients treated for prurigo nodularis developed neuropathy.
53. Offidani M, Corvatta L, Marconi M, et al. Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. Eur J Haematol 2004; 72:403-409. This describes a series of 59 patients treated with thalidomide alone or in combination with oral melphalan. The incidence of neuropathy is similar to the other studies. In addition, the authors report that in patients with advanced multiple myeloma a thalidomide dose of 150 mg/day minimizes peripheral neuropathy without compromising treatment efficacy.
54. Tosi P, Zamagni E, Cellini C, et al. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 2005; 74:212-216. This study examined the long-term toxicity profile of 40 patients with multiple myeloma who received 200-400 mg/day of thalidomide for longer than 12 months. Seventy-five percent developed neurotoxicity and the severity appeared to be correlated more with duration of disease rather than the dose of thalidomide.
55. Perry TA, Weerasuriya A, Mouton PR, et al. Pyridoxine-induced toxicity in rats: a stereological quantification of the sensory neuropathy. Exp Neurol 2004; 190:133-144. This study used stereological and electrophysiological techniques to measure the morphological and physiological changes in dorsal root ganglia and sciatic nerve after pyridoxine intoxication.
56. Callizot N, Warter JM, Poindron P. Pyridoxine-induced neuropathy in rats: a sensory neuropathy that responds to 4-methylcatechol. Neurobiol Dis 2001; 8:626-635.
57. Arkaravichien T, Sattayasai N, Daduang S, Sattayasai J. Dose-dependent effects of glutamate in pyridoxine-induced neuropathy. Food Chem Toxicol 2003; 41:1375-1380.
58. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129:776-783. This study described 32 consecutive patients with previously untreated symptomatic multiple myeloma who received bortezomib, alone or in combination with dexamethasone. The most common side effect was sensory neuropathy, occurring in 31% of patients.
59. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-2617.
60. Cersosimo RJ. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 2005; 39:128-135. This is a good review of the incidence, mechanism, signs, symptoms, and management of oxaliplatin-induced neurotoxicity.
61. Krishnan AV, Goldstein D, Friedlander M, Kieman MC. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 2005; 32:51-60. This was a clinical, and electrophysiological study of 16 patients with neuropathy from oxaliplatin. Besides standard nerve conduction, nerve excitability studies were also performed on these patients. The authors suggest that changes in nerve excitability and refractoriness can possibly explain some of the acute manifestation of this neuropathy.
62. Kuwabara S, Ogawara K, Sung JY, et al. Differences in membrane properties of axonal and demyelinating Guillain-Barré syndromes. Ann Neurol 2002; 52:180-187.
63. Zhuang SH, Agrawal M, Edgerly M, et al. A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer 2005; 103:1932-1938. This was a phase I study of ixabepilone in 26 patients. Only mild non-dose limiting peripheral neuropathy is reported.
64. Martin K, Bentaberry F, Dumoulin C, et al. Neuropathy associated with leflunomide: a case series. Ann Rheum Dis 2005; 64:649-650. This reports on a case-series of 14 patients who developed neuropathy after they were treated with leflunomide for rheumatoid arthritis.